Product nameAnti-PI 3 Kinase p85 alpha antibody [EPR5513]
See all PI 3 Kinase p85 alpha primary antibodies
DescriptionRabbit monoclonal [EPR5513] to PI 3 Kinase p85 alpha
Tested applicationsSuitable for: WBmore details
Unsuitable for: Flow Cyt,ICC,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide corresponding to a region within the N terminus of Human PI 3 Kinase p85 alpha (UniProt ID: P27986)
- Jurkat, Raji, K562, MCF7, C6, Raw 264.7, PC12, NIH3T3 cell lysates
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Dissociation constant (KD)KD = 5.50 x 10 -12 M Learn more about KD
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab133595 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 85 kDa (predicted molecular weight: 83 kDa).|
FunctionBinds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.
Tissue specificityIsoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).
Sequence similaritiesBelongs to the PI3K p85 subunit family.
Contains 1 Rho-GAP domain.
Contains 2 SH2 domains.
Contains 1 SH3 domain.
DomainThe SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.
modificationsPolyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.
Phosphorylated. Dephosphorylated by PTPRJ.
- Information by UniProt
- GRB1 antibody
- p85 alpha antibody
- p85 antibody
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: PI 3 Kinase p85 alpha knockout HAP1 cell lysate (20 µg)
Lane 3: Jurkat cell lysate (20 µg)
Lane 4: THP1 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab133595 observed at 90 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab133595 was shown to specifically react with PI 3 Kinase p85 alpha when PI 3 Kinase p85 alpha knockout samples were used. Wild-type and PI 3 Kinase p85 alpha knockout samples were subjected to SDS-PAGE. ab133595 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/2000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10000 dilution for 1 h at room temperature before imaging.
All lanes : Anti-PI 3 Kinase p85 alpha antibody [EPR5513] (ab133595) at 1/1000 dilution
Lane 1 : Jurkat cell lysate
Lane 2 : Raji cell lysate
Lane 3 : K562 cell lysate
Lane 4 : MCF7 cell lysate
Lane 5 : C6 cell lysate
Lane 6 : Raw 264.7 cell lysate
Lane 7 : PC12 cell lysate
Lane 8 : NIH3T3 cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled Goat anti Rabbit at 1/2000 dilution
Predicted band size: 83 kDa
Equilibrium disassociation constant (KD)
Learn more about KD
Click here to learn more about KD
This product has been referenced in:
- Molinaro A et al. Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Ka and PI3Kß Activities and Is Promoted by RAS. Cell Metab 29:1400-1409.e5 (2019). Read more (PubMed: 30982732) »
- Zhu B et al. Downregulation of Krüppel-like factor 1 inhibits the metastasis and invasion of cervical cancer cells. Mol Med Rep 18:3932-3940 (2018). Read more (PubMed: 30132534) »